The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Besides the broad development of nanotechnological approaches for cancer diagnosis and
therapy, currently, there is no significant progress in the treatment of different types of brain …

Pathologies of the brain, of which brain cancer, Alzheimer's disease, Parkinson's disease,
stroke, and multiple sclerosis, are some of the most prevalent, and that presently are poorly …

The blood–brain barrier (BBB) is a specialized semipermeable structure that highly
regulates exchanges between the central nervous system parenchyma and blood vessels …

Current strategies to direct therapy-loaded nanoparticles to the brain rely on functionalizing
nanoparticles with ligands which bind target proteins associated with the blood–brain barrier …

Nanoparticles have received much attention in biomedical applications due to their unique
physicochemical properties. The metal/metal oxide nanoparticles are involved in various …

Although some tumor has become a curable disease for many patients, involvement of the
central nervous system (CNS) is still a major concern. The blood–brain barrier (BBB), a …

Drug delivery to the brain has been one of the toughest challenges researchers have faced
to develop effective treatments for brain diseases. Owing to the blood–brain barrier (BBB) …

Extensive research into prodrug modification of active pharmaceutical ingredients and
nanoparticle drug delivery systems has led to unprecedented levels of control over the …

Neuroinflammation, an inflammatory response within the central nervous system (CNS), is a
main hallmark of common neurodegenerative diseases, including Alzheimer's disease (AD) …